<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856930</url>
  </required_header>
  <id_info>
    <org_study_id>ANB019-208</org_study_id>
    <nct_id>NCT04856930</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnaptysBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnaptysBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Imsidolimab (ANB019) in Subjects with Hidradenitis Suppurativa&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the efficacy and safety of imsidolimab in adult subjects with hidradenitis&#xD;
      suppurativa (HS). This study also will characterize the pharmacokinetic (PK) profile of&#xD;
      imsidolimab and explore the immune response to imsidolimab in subjects with HS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of imsidolimab in subjects with HS</measure>
    <time_frame>Change in baseline in abscess and inflammatory nodule (AN) count at Week 16</time_frame>
    <description>To evaluate the efficacy of imsidolimab in subjects with HS and compare with placebo change from Baseline in abscess and inflammatory nodule (AN) count at Week 16</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>ANB019 Biological Humanized Monoclonal Antibody Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ANB019 Biological Humanized Monoclonal Antibody High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Imsidolimab</intervention_name>
    <description>Humanized Monoclonal Antibody</description>
    <arm_group_label>ANB019 Biological Humanized Monoclonal Antibody High Dose</arm_group_label>
    <arm_group_label>ANB019 Biological Humanized Monoclonal Antibody Low Dose</arm_group_label>
    <other_name>ANB019</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18 to 75 years (inclusive) at the time of signing informed&#xD;
             consent.&#xD;
&#xD;
          2. Clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months&#xD;
             before Day 1.&#xD;
&#xD;
          3. HS lesions present in at least 2 distinct anatomical areas.&#xD;
&#xD;
          4. Total AN count ≥ 5.&#xD;
&#xD;
          5. Draining fistulas ≤ 20.&#xD;
&#xD;
          6. Stable HS for at least 6 weeks prior to Day 1 visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Concomitant dermatological or medical conditions that may interfere with the&#xD;
        Investigators' ability to evaluate the subject's response to therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Randazzo, MD</last_name>
    <role>Study Director</role>
    <affiliation>AnaptysBio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Iheanacho, MS</last_name>
    <phone>(240) 676-3114</phone>
    <email>info@anaptysbio.com</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL-36 receptor</keyword>
  <keyword>Interleukin 36</keyword>
  <keyword>Imsidolimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

